文献速递冠心病

急性冠脉综合征支架术后1个月内停用阿司匹林改用替格瑞洛单药治疗:T-PASS随机非劣效性试验

Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
PubMed 文献 · Circulation · 2023-10-25

T-PASS试验纳入2850例接受药物洗脱支架植入的急性冠脉综合征患者,随机比较双联抗血小板治疗不足1个月后替格瑞洛单药与12个月替格瑞洛为基础的双联抗血小板治疗。1年时替格瑞洛单药组主要终点事件发生率2.8%,双联组5.2%(HR 0.54,95%CI 0.37-0.80),非劣效且优效;大出血发生率单药组1.2%显著低于双联组3.4%。

要点

  • ACS患者DES植入后<1个月停阿司匹林,替格瑞洛单药1年净临床获益非劣且优于12个月DAPT。
  • 主要获益来自大出血显著减少(1.2% vs 3.4%,HR 0.35)。
  • 试验事件率低,可能入选非高危患者,解读需考虑。

核心结论

  • 在ACS接受DES植入的患者中,<1个月DAPT后替格瑞洛单药治疗1年复合终点(死亡、心梗、支架血栓、卒中、大出血)非劣且优于12个月替格瑞洛为基础DAPT。
  • 获益主要由于大出血显著减少。

研究设计与样本

  • 随机、开放标签、非劣效性试验,在韩国24个中心纳入2850例ACS接受DES植入患者,1:1随机分为替格瑞洛单药组(n=1426)和12个月替格瑞洛为基础DAPT组(n=1424)。
  • 替格瑞洛单药组在DAPT<1个月后停用阿司匹林,阿司匹林中位停药时间16天(IQR 12-25天)。
  • 主要终点为1年时全因死亡、心肌梗死、确定或可能支架血栓、卒中及大出血的复合终点,在意向治疗人群分析。

主要发现

  • 主要终点在替格瑞洛单药组发生40例(2.8%),12个月DAPT组73例(5.2%)(HR 0.54,95%CI 0.37-0.80;非劣效P<0.001;优效P=0.002)。
  • 大出血在替格瑞洛单药组1.2%,12个月DAPT组3.4%(HR 0.35,95%CI 0.20-0.61;P<0.001)。
  • 符合方案人群敏感性分析结果一致。

临床怎么用

  • ACS患者DES植入后,可考虑在DAPT不足1个月时停用阿司匹林,改用替格瑞洛单药治疗以降低出血风险并维持缺血获益。
  • 需注意该试验事件率低,可能入选相对非高危患者,临床决策应结合患者缺血与出血风险个体化。

局限性

  • 事件率低,可能提示入选患者相对非高危。
  • 开放标签设计。
  • 研究在韩国单一人群进行,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stopping aspirin within 1 month after implantation of a drug-eluting stent for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome. The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with acute coronary syndrome. METHODS: In this randomized, open-label, noninferiority trial, 2850 patients with acute coronary syndrome who underwent drug-eluting stent implantation at 24 centers in South Korea were randomly assigned (1:1) to receive either ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426) or 12 months of ticagrelor-based DAPT (n=1424) between April 24, 2019, and May 31, 2022. The primary end point was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. Key secondary end points were the individual components of the primary end point. RESULTS: Among 2850 patients who were randomized (mean age, 61 years; 40% ST-segment-elevation myocardial infarction), 2823 (99.0%) completed the trial. Aspirin was discontinued at a median of 16 days (interquartile range, 12-25 days) in the group receiving ticagrelor monotherapy after <1 month of DAPT. The primary end point occurred in 40 patients (2.8%) in the group receiving ticagrelor monotherapy after <1-month DAPT, and in 73 patients (5.2%) in the ticagrelor-based 12-month DAPT group (hazard ratio, 0.54 [95% CI, 0.37-0.80]; P<0.001 for noninferiority; P=0.002 for superiority). This finding was consistent in the per-protocol population as a sensitivity analysis. The occurrence of major bleeding was significantly lower in the ticagrelor monotherapy after <1-month DAPT group compared with the 12-month DAPT group (1.2% versus 3.4%; hazard ratio, 0.35 [95% CI, 0.20-0.61]; P<0.001). CONCLUSIONS: This study provides evidence that stopping aspirin within 1 month for ticagrelor monotherapy is both noninferior and superior to 12-month DAPT for the 1-year composite outcome of death, myocardial infarction, stent thrombosis, stroke, and major bleeding, primarily because of a significant reduction in major bleeding, among patients with acute coronary syndrome receiving drug-eluting stent implantation. Low event rates, which may suggest enrollment of relatively non-high-risk patients, should be considered in interpreting the trial. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03797651.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Hong, Lee, Suh, et al. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial. Circulation. 2023. PMID: 37878786. doi:10.1161/CIRCULATIONAHA.123.066943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。